Cerus Company Insiders
CERS Stock | USD 1.45 0.00 0.00% |
Cerus' insiders are aggressively selling. The analysis of insiders' sentiment of trading Cerus stock suggests that vertually all insiders are panicking at this time. Cerus employs about 614 people. The company is managed by 18 executives with a total tenure of roughly 76 years, averaging almost 4.0 years of service per executive, having 34.11 employees per reported executive.
William Greenman CEO CEO and President and Director |
Laurence Corash President Senior Vice President Chief Medical and Chief Scientific Officer, Director |
Insider Sentiment 0
Mostly Selling
Selling | Buying |
Latest Trades
2025-03-13 | William Mariner Greenman | Disposed 71086 @ 1.45 | View | ||
2025-03-07 | William Mariner Greenman | Disposed 60984 @ 1.5 | View | ||
2025-03-04 | William Mariner Greenman | Disposed 23023 @ 1.55 | View | ||
2025-03-03 | Kevin Dennis Green | Disposed 60656 @ 1.58 | View | ||
2024-12-12 | Eric Bjerkholt | Disposed 20000 @ 1.78 | View | ||
2024-09-03 | Kevin Dennis Green | Disposed 28385 @ 2.18 | View | ||
2024-08-02 | Richard J Benjamin | Disposed 21605 @ 2.5 | View |
Monitoring Cerus' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cerus. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. Cerus Management Team Effectiveness
The company has return on total asset (ROA) of (0.0382) % which means that it has lost $0.0382 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3569) %, meaning that it created substantial loss on money invested by shareholders. Cerus' management efficiency ratios could be used to measure how well Cerus manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.11 in 2025. Return On Capital Employed is likely to drop to -0.11 in 2025. At this time, Cerus' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 33.6 M in 2025, whereas Total Current Assets are likely to drop slightly above 101.9 M in 2025.Common Stock Shares Outstanding is likely to gain to about 193.8 M in 2025, whereas Net Loss is likely to drop (40.4 M) in 2025.
Cerus Workforce Comparison
Cerus is rated fifth in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 8,408. Cerus holds roughly 614 in number of employees claiming about 7% of equities under Health Care industry.
Cerus Profit Margins
The company has Profit Margin (PM) of (0.1) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.14) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.14.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.68 | 0.5521 |
|
|
Cerus Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cerus insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cerus' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Cerus insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Witney Frank over three months ago Acquisition by Witney Frank of 40000 shares of Cerus at 5.0 subject to Rule 16b-3 | ||
Vivek Jayaraman over three months ago Acquisition by Vivek Jayaraman of 90486 shares of Cerus subject to Rule 16b-3 | ||
Richard Benjamin over three months ago Disposition of 30075 shares by Richard Benjamin of Cerus at 1.45 subject to Rule 16b-3 | ||
William Greenman over three months ago Disposition of 60984 shares by William Greenman of Cerus at 1.498 subject to Rule 16b-3 | ||
Richard Benjamin over three months ago Disposition of 261 shares by Richard Benjamin of Cerus at 1.498 subject to Rule 16b-3 | ||
Richard Benjamin over three months ago Disposition of 6292 shares by Richard Benjamin of Cerus at 1.5485 subject to Rule 16b-3 | ||
Richard Benjamin over three months ago Disposition of 13912 shares by Richard Benjamin of Cerus subject to Rule 16b-3 | ||
Richard Benjamin over three months ago Acquisition by Richard Benjamin of 13912 shares of Cerus subject to Rule 16b-3 |
Cerus Notable Stakeholders
A Cerus stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cerus often face trade-offs trying to please all of them. Cerus' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cerus' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Laurence MD | CoFounder Officer | Profile | |
William Greenman | CEO and President and Director | Profile | |
Laurence Corash | Senior Vice President Chief Medical and Chief Scientific Officer, Director | Profile | |
Kevin Green | CFO and VP of Fin. | Profile | |
Kevin CPA | VP CFO | Profile | |
Carol Moore | Sr. VP of Regulatory Affairs, Quality and Clinical | Profile | |
Lainie Corten | Sr. Director, Global Marketing & Investor Relations | Profile | |
Lori Roll | VP Secretary | Profile | |
Matthew Notarianni | Director Relations | Profile | |
Richard Benjamin | Chief Medical Officer | Profile | |
Vivek Jayaraman | Chief Commercial Officer | Profile | |
Chrystal Jensen | Chief Counsel | Profile | |
Jessica Hanover | Vice Affairs | Profile | |
Chrystal Menard | Chief Legal Officer | Profile | |
Dr MBChB | Chief Officer | Profile | |
Alicia Goodman | Chief Officer | Profile | |
Chrystal JD | General Officer | Profile | |
Nina Mufti | Senior Development | Profile |
About Cerus Management Performance
The success or failure of an entity such as Cerus often depends on how effective the management is. Cerus management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cerus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cerus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.10) | (0.11) | |
Return On Capital Employed | (0.10) | (0.11) | |
Return On Assets | (0.10) | (0.11) | |
Return On Equity | (0.37) | (0.39) |
Please note, the imprecision that can be found in Cerus' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cerus. Check Cerus' Beneish M Score to see the likelihood of Cerus' management manipulating its earnings.
Cerus Workforce Analysis
Traditionally, organizations such as Cerus use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cerus within its industry.Cerus Manpower Efficiency
Return on Cerus Manpower
Revenue Per Employee | 293.6K | |
Revenue Per Executive | 10M | |
Net Loss Per Employee | 34.1K | |
Net Loss Per Executive | 1.2M | |
Working Capital Per Employee | 144K | |
Working Capital Per Executive | 4.9M |
Additional Tools for Cerus Stock Analysis
When running Cerus' price analysis, check to measure Cerus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cerus is operating at the current time. Most of Cerus' value examination focuses on studying past and present price action to predict the probability of Cerus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cerus' price. Additionally, you may evaluate how the addition of Cerus to your portfolios can decrease your overall portfolio volatility.